The concept of Raynaud's phenomenon of the lung revisited

Lung Function Laboratory, Hopitaux Universitaires, Strasbourg, France.
The American Journal of Medicine (Impact Factor: 5). 12/1996; 101(5):468-71. DOI: 10.1016/S0002-9343(96)00256-2
Source: PubMed


Having observed that a cold pressor test (CPT) induces a decrease in carbon monoxide single breath diffusing capacity (DLco) in normal subjects contrary to the findings of Fahey et al (Am J Med. 1984; 76:263-269), we compared the response to CPT for the two types of Raynaud's phenomenon.
Two groups of 8 patients suffering from primary or secondary Raynaud's phenomenon were examined.
Single breath diffusing capacity, mean pulmonary artery pressure (PAP), cardiac output (CO), pulmonary capillary wedge pressure (PwP), and pulmonary vascular resistance (PVR) were measured before and 30 minutes after CPT, which consisted of immersing both hands in a water bath at 12 degrees C for 2 minutes.
Cold pressor testing induced no change in DLco or cardiovascular parameters in patients with secondary Raynaud's phenomenon. Conversely, in patients with the primary form, it induced a significant decrease in DLco (16%), PAP (20%), and PVR (27%), whereas CO and PwP remained unaltered.
The concept of pulmonary Raynaud's phenomenon had to be reconsidered, as it is also observed in normal subjects, and is due to a vasodilatation and not to a vasoconstriction of the pulmonary artery (Frans et al, J Appl Physiol. 1994; 76:750-755). In patients with primary Raynaud's phenomenon, the decrease in DLco is not only a physiological response, but a pathological response to a CPT, as it is significantly more marked in patients than in control subjects (16% versus 10% for controls, same reference). The contribution by Fahey et al remains important, however, in that it allows assessing whether a patient with Raynaud's phenomenon suffers from the primary or secondary form of the disease.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Scleroderma is a descriptive construct that defines a large family of ­diseases characterized clinically by thickening of the skin. Systemic sclerosis (SSc) is a complex disease affecting multiple organ systems and is the most ­representative and prevalent of this spectrum of disorders. Generalized subcutaneous morphea (GSM, morphea profunda) is a form of localized scleroderma that tends to spare the internal organs. We are presenting two cases illustrating the aforementioned clinical entities.
    Journal of the Indian Medical Association 06/1965; 44:484-6. DOI:10.1007/978-1-60761-296-4_18
  • Article: Scleroderma
    [Show abstract] [Hide abstract]
    ABSTRACT: Scleroderma presents a formidable therapeutic challenge for both the physician and the patient. Over the years many medications and interventions have been reported to be beneficial in scleroderma. With equal regularity, however, when put to the test of the randomized controlled trial, many of these same medications have subsequently been shown to be ineffective. This is true for both the localized and systemic forms of the disease. Two of the most recent additions to this inauspicious list for systemic sclerosis include D-penicillamine and methotrexate. At the very least these outcomes should point to our deficiencies in understanding the pathogenesis of this unusual disorder. It should raise the possibility that collagen and inflammatory or immune cells are not good therapeutic targets and new targets should be sought. Despite the scope of these problems and the lack of definitive therapy, there is a great deal an individual physician can do to help a patient living with scleroderma. This article presents management approaches to patients with either localized or systemic scleroderma.
    Dermatologic Therapy 05/2001; 14(2):81 - 94. DOI:10.1046/j.1529-8019.2001.014002081.x · 1.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background In type II diabetes mellitus there are few data concerning pulmonary function abnormalities. In normal subjects and in patients with primary Raynaud phenomenon, cold pressor test induces a decrease in carbon monoxide single-breath diffusing capacity (DL,co) but not in secondary Raynaud phenomenon. Our objective was to assess evaluation of lung diffusion capacity postural changes in diabetes mellitus and in secondary Raynaud phenomenon, two diseases with different pulmonary capillaries functional disorders.
    Archives of Medical Research 11/2002; 33(6):531-535. DOI:10.1016/S0188-4409(02)00401-0 · 2.65 Impact Factor
Show more